Massachusetts Governor Proposes $1B Stem-Cell Plan
Governor Deval Patrick of Massachusetts has proposed a plan for committing $1-billion over the next decade to life-sciences research, including the creation of a stem-cell bank, in an effort to make the state a global leader in biotechnology.
Governor Deval Patrick of Massachusetts has proposed a plan for committing $1-billion over the next decade to life-sciences research, including the creation of a stem-cell bank, in an effort to make the state a global leader in biotechnology.
The plan, outlined during a speech at the BIO 2007 convention held at Boston, includes a 10-year, $1 billion investment package to ensure the state’s ability to support life sciences progress “from the idea stage through the production stage.”
The initiative calls for the creation of a stem-cell bank that will serve a centralized repository of stem-cell lines for public and private research. Boston University, Brigham and Women’s, Children’s Hospital, Harvard University, the Massachusetts Institute of Technology, Massachusetts General Hospital, Partners HealthCare, and the University of Massachusetts have already agreed to participate in the bank when it is completed.
Key to the Governor’s plan is new legislation to strengthen the Massachusetts Life Science Center and charge it with the execution of a life sciences mission focused on science and economic development, strategic investments at critical stages of the development cycle, and collaboration with the private sector to create innovation infrastructure critical to both researchers and companies.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Filter Sizing for Process Optimization in Life Sciences Sterile Filtration
April 24th 2025Bench-scale filterability studies play a critical role in optimizing sterile filtration in biopharmaceutical manufacturing. By guiding the selection and sizing of filters, these studies help streamline processes, improve scalability, and reduce costs. Through data-driven case studies, this paper highlights how the strategic use of pre-filters and membrane materials can maximize throughput and minimize filter fouling.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
